诺迪康品牌怎么样 申请店铺

我要投票 诺迪康在中草药行业中的票数:345 更新时间:2025-05-10
诺迪康是哪个国家的品牌?「诺迪康」是 西藏诺迪康药业股份有限公司 旗下著名品牌。该品牌发源于西藏,由创始人陈达彬在1999-07-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺迪康品牌出海!将品牌入驻外推网,定制诺迪康品牌推广信息,可以显著提高诺迪康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

诺迪康怎么样

西藏诺迪康药业股份有限公司是西藏雪域高原上诞生的第一家高新技术制药上市企业,于1999年7月14日创立,1999年7月21日在上海证券交易所上网交易,股票名称:西藏药业,股票代码:600211。

在各级领导的关心和支持下,公司已经发展成为一家拥有员工4000余人,总资产8.2亿元的现代化制药企业。公司累计上缴税金2亿余元,发放员工工资、福利2.2亿余元;公司主要产品诺迪康胶囊年销售额逾亿元,公司生物一类新药重组人脑利钠肽也已经上市销售。

公司拥有西藏诺迪康医药有限公司、成都诺迪康生物制药有限公司、四川诺迪康威光制药有限公司、西藏康达药业有限公司、西藏诺迪康藏药材开发有限公司、四川本草堂药业有限公司等下属子公司。

公司秉承“科学成就健康,健康成就未来”的理念,以科技兴业。在为藏药现代化不遗余力的同时,公司注巨资于生物制品和传统药品的研发,并构建了林芝种植基地和四个生产基地及覆盖全国的营销网络。产品涵盖生物制品、藏药和中药、化学药的产品系列,奠定了西藏药业持续发展的基础,其中具有自主知识产权的生物制品一类新药新活素,代表着目前国际急性心衰急救治疗药物的最高水平,填补了该领域的国内空白。

公司上市以来连续被西藏自治区认定为高新技术企业、西藏自治区农牧业龙头企业,2001年被国家科学技术部认定为国家火炬计划重点高新技术企业。2008年公司被科技部认定为创新型试点企业。公司图形商标(祥云图)经国家工商总局认定为中国驰名商标,公司产品诺迪康胶囊和十味蒂达胶囊被评为国家中药保护品种,同时,还被国家保密局、科学技术部评为秘密级国家秘密技术。

经过多年来的不懈努力,公司已成为拥有一个国家级企业技术中心、四个符合GMP规范的药品生产基地、一个符合GAP藏药材种植基地及覆盖全国的营销网络,集藏药产品、植物药产品、化学药产品、生物制品研发、生产和销售一体的现代化企业。

Tibet nordikang Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise born on the snow capped plateau of Tibet. It was founded on July 14, 1999 and traded on the Internet at Shanghai Stock Exchange on July 21, 1999. Its stock name is Tibet pharmaceutical, and its stock code is 600211. With the concern and support of leaders at all levels, the company has developed into a modern pharmaceutical enterprise with more than 4000 employees and total assets of 820 million yuan. The company has paid taxes of more than 200 million yuan and paid employees salaries and welfare of more than 220 million yuan; the annual sales volume of the company's main product, nordicon capsule, is more than 100 million yuan, and the company's new biological class I recombinant human brain natriuretic peptide has also been listed for sale. The company has subsidiaries including Tibet nordikang Pharmaceutical Co., Ltd., Chengdu nordikang biopharmaceutical Co., Ltd., Sichuan nordikang Weiguang Pharmaceutical Co., Ltd., Tibet Kangda Pharmaceutical Co., Ltd., Tibet nordikang Tibetan Medicine Development Co., Ltd., Sichuan bencaotang Pharmaceutical Co., Ltd. The company adheres to the concept of "science makes health, health makes future", and prospers with science and technology. While sparing no effort for the modernization of Tibetan medicine, the company has invested heavily in the research and development of biological products and traditional drugs, and has built the Linzhi planting base, four production bases and a nationwide marketing network. The products range from biological products, Tibetan medicine, traditional Chinese medicine and chemical medicine, laying the foundation for the sustainable development of Tibetan pharmaceutical industry, among which the biological products with independent intellectual property rights represent the highest level of international emergency treatment drugs for acute heart failure, and fill the domestic gap in this field. Since its listing, the company has been successively recognized as a high-tech enterprise in Tibet Autonomous Region, a leading enterprise in agriculture and animal husbandry in Tibet Autonomous Region, and a key high-tech enterprise in the national torch plan by the Ministry of science and technology of the people's Republic of China in 2001. In 2008, the company was recognized as an innovative pilot enterprise by the Ministry of science and technology. The company's graphic trademark (xiangyuntu) has been recognized as a well-known trademark in China by the State Administration of industry and commerce. The company's products, nordikang capsule and Shiweidida capsule, have been rated as the national traditional Chinese medicine protected varieties. Meanwhile, they have also been rated as the secret level national secret technology by the State Security Bureau and the Ministry of science and technology. After years of unremitting efforts, the company has become a modern enterprise with a national enterprise technology center, four GMP compliant pharmaceutical production bases, a gap compliant Tibetan medicine planting base and a nationwide marketing network, which integrates the research and development, production and sales of Tibetan medicine products, botanical medicine products, chemical medicine products and biological products.

本文链接: https://brand.waitui.com/0b45a7af1.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

奥乐齐昆山首店正式开业

36氪获悉,5月10日,奥乐齐ALDI位于昆山的首家门店正式开业。这是奥乐齐在苏州、无锡成功开设两家门店且大受本地居民欢迎与认可之后,于江苏地区布局的又一重要里程碑。短时间内在苏锡昆“连开三店”,不仅凸显出奥乐齐广受当地受众认可,亦彰显了其对本地消费市场的坚定信心,更标志着品牌在江苏市场战略布局的进一步拓展与深化。

2小时前

浙江大学董雪兵:强化产业创新协同 发挥区域战略叠加效应

5月9日,2025长三角粤港澳国家战略联动发展论坛在广州举行。论坛前夕,上海证券报记者就如何深化区域联动等问题,采访浙江大学区域协调发展研究中心副主任董雪兵。董雪兵认为,长三角、粤港澳大湾区等重点区域应在服务国家战略需求的基础上,发挥战略叠加效应,实现进一步联动发展。以产业协同为例,长三角和粤港澳大湾区可以发挥各自优势,围绕生物医药、人工智能、集成电路等双方均具优势的领域,开展创新链、产业链、供应链和价值链的空间融合,共同打造全国领先的产业集群。(上证报)

2小时前

永达股份:子公司部分产品应用于机器人领域,业务规模尚小

永达股份(001239)5月9日在业绩说明会上表示,公司控股子公司江苏金源高端装备有限公司部分产品应用于机器人领域,但在此领域的业务规模尚小。(e公司)

2小时前

《中国企业海外传播力分析报告(2024)》正式发布

《中国企业海外传播力分析报告(2024)》在于浙江德清举办的2025世界品牌莫干山大会上正式发布。《报告》发现,中国企业的国际传播及形象打造策略获得实效。中国企业早期的形象宣传多集中于技术革新的宏大叙事或文化符号的堆叠,而当前实践更强调多维度资源的整合。中国企业的海外形象建构策略正在经历从“单一功能输出”向“多维价值融合”的转型,其核心在于通过技术、文化与社会责任的动态协同,构建更具韧性的品牌叙事。例如,作为中国全球化企业代表之一,海信将“环境、社会、治理”(ESG)理念深度融入全球化发展,构建了独具特色的国际传播模式。(财联社)

2小时前

烨隆股份撤回上市申请

上海证券报记者从上交所获悉,过会已一年多的无锡烨隆精密机械股份有限公司5月8日撤回上市申请,上交所主板IPO终止。(上证报)

2小时前

本页详细列出关于诺迪康的品牌信息,含品牌所属公司介绍,诺迪康所处行业的品牌地位及优势。
咨询